These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 12828668)

  • 1. The pharmacokinetics of clotting factor therapy.
    Berntorp E; Björkman S
    Haemophilia; 2003 Jul; 9(4):353-9. PubMed ID: 12828668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant factor VIIa concentrate versus plasma-derived concentrates for treating acute bleeding episodes in people with haemophilia and inhibitors.
    Matino D; Makris M; Dwan K; D'Amico R; Iorio A
    Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD004449. PubMed ID: 26677005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel therapeutic approach combining human plasma-derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone.
    Tomokiyo K; Nakatomi Y; Araki T; Teshima K; Nakano H; Nakagaki T; Miyamoto S; Funatsu A; Iwanaga S
    Vox Sang; 2003 Nov; 85(4):290-9. PubMed ID: 14633255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa.
    Lindley CM; Sawyer WT; Macik BG; Lusher J; Harrison JF; Baird-Cox K; Birch K; Glazer S; Roberts HR
    Clin Pharmacol Ther; 1994 Jun; 55(6):638-48. PubMed ID: 8004880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Importance of pharmacokinetics in the management of hemophilia.
    Barnes C
    Pediatr Blood Cancer; 2013; 60 Suppl 1():S27-9. PubMed ID: 23109436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant Factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with haemophilia and inhibitors.
    Iorio A; Matino D; D'Amico R; Makris M
    Cochrane Database Syst Rev; 2010 Aug; (8):CD004449. PubMed ID: 20687076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment on demand--in vivo dose finding studies.
    Escobar MA
    Haemophilia; 2003 Jul; 9(4):360-7. PubMed ID: 12828669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Setting the stage for individualized therapy in hemophilia: What role can pharmacokinetics play?
    Hazendonk HCAM; van Moort I; Mathôt RAA; Fijnvandraat K; Leebeek FWG; Collins PW; Cnossen MH;
    Blood Rev; 2018 Jul; 32(4):265-271. PubMed ID: 29426727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of plasma-derived and recombinant factor IX: using population pharmacokinetics with sparse sampling data needs further study.
    Berntorp E
    Haemophilia; 2013 Nov; 19(6):805-7. PubMed ID: 24165154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia.
    Björkman S; Berntorp E
    Clin Pharmacokinet; 2001; 40(11):815-32. PubMed ID: 11735604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative pharmacokinetics of factor VIII and recombinant factor IX: for which coagulation factors should half-life change with age?
    Björkman S
    Haemophilia; 2013 Nov; 19(6):882-6. PubMed ID: 24165155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Secondary prophylaxis with factor IX concentrates: continuous infusion.
    Morfini M
    Blood Transfus; 2008 Sep; 6 Suppl 2(Suppl 2):s21-5. PubMed ID: 19105506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Haemophilia].
    Loomans JI; Lock J; Peters M; Leebeek FW; Cnossen MH; Fijnvandraat K
    Ned Tijdschr Geneeskd; 2014; 158():A7357. PubMed ID: 25351381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuous infusion of recombinant factor VIIa in patients with haemophilia and inhibitors. Experience in The Netherlands and Belgium.
    Mauser-Bunschoten EP; de Goede-Bolder A; Wielenga JJ; Levi M; Peerlinck K
    Neth J Med; 1998 Dec; 53(6):249-55. PubMed ID: 9883002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B.
    Stobart K; Iorio A; Wu JK
    Cochrane Database Syst Rev; 2005 Apr; (2):CD003429. PubMed ID: 15846666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New products for the treatment of haemophilia.
    Laffan M
    Br J Haematol; 2016 Jan; 172(1):23-31. PubMed ID: 26456702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complications with clotting-factors.
    Lancet; 1972 Apr; 1(7753):729-30. PubMed ID: 4111198
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacokinetic and safety considerations when switching from standard to extended half-life clotting factor concentrates in hemophilia.
    Morfini M; Farrugia A
    Expert Rev Hematol; 2019 Oct; 12(10):883-892. PubMed ID: 31314609
    [No Abstract]   [Full Text] [Related]  

  • 19. Rapid rFVIIa enhanced on-demand dosing in haemophilia inhibitor patients.
    Morfini M
    Eur J Haematol; 2016 Feb; 96(2):111-8. PubMed ID: 26172449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors: overall rFVIIa exposure and intervals following high (>240 μg kg⁻¹) rFVIIa doses across clinical trials and registries.
    Shapiro AD; Neufeld EJ; Blanchette V; Salaj P; Gut RZ; Cooper DL
    Haemophilia; 2014 Jan; 20(1):e23-31. PubMed ID: 24354484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.